Immunovant, Inc. · NASDAQ:IMVT
Immunovant — Investor Presentation (September 2021)
7 slides from Immunovant's investor presentation, Sep 15, 2021
Slide 1: Myasthenia Gravis Patient Insights Investor Presentation
Myasthenia Gravis Patient Insights Investor Presentation September 2021 EExhibit 99.2
Slide 2: Forward-looking statements
Forward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “expect,” “plan,” “anticipa
Slide 3: Rethinking possibilities in autoimmune disease
Rethinking possibilities in autoimmune disease 3 Love Trailblazing All Voices Bolder Faster Our vision: Normal lives for people with autoimmune diseases
Slide 4: Fifteen indications announced by at least one anti-FcRn program
4 Fifteen indications announced by at least one anti-FcRn program Anti-FcRn Market: Potential therapeutic benefit across wide range of indications ENDOCRINOLOGY Thyroid eye disease RHEUMATOLOGY Primary Sjögrens Syndrome Lupus Nephritis Systemic lupus erythematosus Rheumatoid arthritis DERMATOLOGY Bu
Slide 5: Despite available treatment options, people with Myasthenia Gravis report significant unmet needs
Despite available treatment options, people with Myasthenia Gravis report significant unmet needs 5 • Even well controlled patients report lifestyle accommodations • Anxiety around response and duration Significant impact on QoL Source: Analysis – Social Media Review MG n=975 / Qualitative research
Slide 6: Patient Survey Feedback: Preferred Treatment Approach
Patient Survey Feedback: Preferred Treatment Approach Dosing approach preferences 6Source: Analysis – MG Patient Quantitative Survey (n=50) 94% 6% I want to stay on my MG treatment, even when my symptoms are under control, so that I can maintain a response and prevent potential symptom flares I only
Slide 7: Batoclimab's differentiated product attributes provide a unique opportunity to address patient unmet needs
Batoclimab’s differentiated product attributes provide a unique opportunity to address patient unmet needs 7 Subcutaneous route of administration: Designed and developed for simple subcutaneous injection to provide human-centric dosing experience Significant impact on QoL Reliable treatment options